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Background: Gingival enlargement (GE) is a fre- 
quent side effect that occurs in organ transplant recip- 
ients (OTR) after the administration of cyclosporin A 
(CsA). The availability of new drugs used to suppress 
graft rejection in OTR offers an opportunity to man- 
age GE non-surgically. This preliminary case series 
aimed to analyze the effect of CsA withdrawal and its 
substitution by another immunosuppressant in OTR 
with severe GE. 
Methods: Four organ transplant recipients who 
had received a liver or renal allograft were recruited 
for this study. Al1 OTR had deueloped clinically severe 
CsA-induced GE. GE scores were assessed for each 
patient at baseline and at weeks 2, 4, 8, 12, 16, and 
54 following conversion to tacrolimus. Scaling and 
root planing were initially performed and repeated 
monthly during the first 6 months. Careful polishing 
of the teeth was carried out once every 2 weeks until 
month 6 and then monthly until month 12. Hygiene 
instructions and reinforcement to optimize oral hygiene 
were maintained throughout the study. 
Results: The four patients showed a rapid decrease 
in their gingiual symptoms and in the size of the gin- 
givae. This change was clinically euident 8 weeks 
after conversion to tacrolimus. One year later, al1 the 
patients experienced GE regression, although some 
anatomic irregularities persisted in the interdental 
papillae of one of the patients. No adverse effects from 
tacrolimus were observed during the study except in 
one patient who presented headaches. 
Conclusion: It seems that CsA withdrawal and its 
conversion to tacrolimus in organ transplant recipients 
who deuelop severe gingiual enlargement, together 
with an extensive plaque control program, provide an 
effective means to control/eliminate gingival hyper- 
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Gingival enlargement (GE) may occur a s  a result of 
the administration of certain drugs, especially pheny- 
toin,' calcium channel b l ~ c k e r s , ~  and cyclosporin A 
( c sA) .~  The incidence of drug-induced GE varies 
according to several factors; however, the exact mech- 
anism for the development of GE is still u n k n ~ w n . ~ ~ ~  
Gingival size in these patients may be affected to dif- 
ferent degrees, from slight overgrowth to severe 
enlargement, which may interfere with oral function 
and create esthetic problems. 
Since its introduction into clinical practice by Calne 
in 1 9 7 8 , ~  CsA has been used during the last 2 decades 
as  the main immunosuppressant to prevent graft rejec- 
tion in solid organ transplant recipients. Its benefits 
have resulted in an important advance in this area of 
medicine, although some side effects may appear, such 
as nephrotoxicity, diabetogenicity, tremor, headache, 
hirsutism, gynecomastia, and gingival enlargement. 
GE prevalence in these patients varies from 8% to 
8 1 % . ~ - ~  Several different factors have been associated 
with its appearance, including the presence of plaque, 
prior inflammation, drug dosage and blood level, length 
of administration, and other ~ a r i a b l e s . ~ ) ~ ~ - ' *  Different 
therapeutic approaches, such as  strict plaque control 
and surgery, have been the treatment of choice in the 
management of GE in these patients. Despite these 
measures, GE usually recurs after severa1 months.13 
Because of the importance of maintaining an immuno- 
suppressive level in these individuals, CsA withdrawal 
was not previously considered as  a therapeutic option 
in the treatment of GE in organ transplant recipients. 
However, the appearance of new immunosuppressive 
1816 Volurne 74 Nurnber 12 
Table l. 
Demographic Details and Characteristics of the Four Transplant Patients 
Serum Initial Serum 
TST Cause of Type of Dose Levels Dose of Levels of Dose of Dose of 
Patient Gender Age (months) Transplantation Transplant of CsA - of CsA Tacrolimus Tacrolimus Azathioprine Prednisone 
I M 58 87 Alcoholic cirhosis L 350 mgld 283 yglml 6 mgld 12.6 yglml - I O mgld 
2 F 49 4 1 Hepatitis C cirrhosis L 300 mg/d 235 yglml I O mgld 14.8 pglrnl - I O mgld 
3 F 38 29 Glomerulonephritis K 250 mgld 256 pglml 7 mgld 10.2 yglml 50 mgld 5 mgld 
4 M 53 72 Hepatoma L 300 rngld 268 yglml I O mgld 1 6.2 yglml - I O mgld 
TST = time since transplantation, L = Iiver; K = kidney. 
drugs in recent years permits conversion from CsA 
to other immunosuppressants as  a safe and secure 
therapeutic alternative. Tacrolimus is a xenobiotic 
immunosuppressant discovered in 1978, which has 
demonstrated high clinical efficacy to avoid graft rejec- 
tion in solid organ transplants, through an action mech- 
anism based on the inhibition of the calcineurin 
pathway.14 Tacrolimus and CsA show major differences 
in their chemical structure, even though they seem to 
have many actions in common as  well a s  a similar 
spectrum of side effects. However, a recent study has 
shown that tacrolimus has no adverse effect on the 
gingival tissues.15 These characteristics have made 
conversion from CsA to tacrolimus desirable in some 
cases to reduce GE without any supplementary surgi- 
cal p r ~ c e d u r e . ' ~ - ~ '  Most of these reports deal with sin- 
gle cases or short series, and the effects of an extensive 
oral hygiene program accompanying the withdrawal 
of CsA have not been previously analyzed.17 The pur- 
pose of this preliminary study was to observe the GE 
course in four transplant recipients receiving CsA fol- 
lowed by conversion to tacrolimus, together with an 
extensive plaque control program. 
MATERIALS AND METHODS 
Four transplant patients who signed an informed con- 
sent were included in this pilot study. Demographic 
characteristics, cause of transplantation, time since 
transplantation, medication, and dosages are pro- 
vided in Table 1. Al1 the patients had received an 
orthotopic liver or kidney transplantation at the Hos- 
pital 12 de Octubre in Madrid at  least 1 year previ- 
ously, and they were under periodic maintenance in 
the Department of Abdominal Transplant Organs 
(three liver transplant patients) and the Department 
of Nephrology (one kidney transplant patient). Al1 
the patients were taking different doses of C S A ~  (Table 
l ) ,  and they were switched to tacrolimus# by the 
transplant team due to the presence of chronic liver 
graft rejection (patients 1 and 2), hirsutism (patient 
3 ) ,  and severe hypertension (patient 4). The patients 
were eligible for enrollment in this study if they exhib- 
ited several criteria, such a s  the presence of clini- 
cally severe GE diagnosed by two dentists with 
experience in this field (GH, LA); were taking differ- 
ent doses of CsA since transplantation; were not tak- 
ing any other medication with known gingival side 
effects; were not suffering from any malignancy or 
systemic disease with proven secondary effects on the 
periodontium; and they complied with a periodic oral 
health care program. Not al1 the patients were 
included in this study at  the same time, since the cir- 
cumstances that led the transplant team to change 
the medication occurred at different times. The four 
patients included in this study were selected over an 
11 -month period. 
One week before withdrawal of CsA, the patients 
were examined according to the clinical protocol used 
by the Department of Oral Medicine and Buccofacial 
Surgery. The initial examination included a complete 
medical history, physical examination, complete blood 
analysis, including blood levels of CsA (Table l ) ,  and 
intraoral examination. Gingival overgrowth was 
assessed by one of the examiners (GH) according 
to the gingival overgrowth index (SI) proposed by 
Seymour et with slight variations. The 10 papil- 
lae between the canines were measured in the lower 
teeth because this area is usually the most commonly 
a f f e ~ t e d . ~ ~ ? ~ ~  Since any gingival unit may reach a 
7 Neoral, Novartis Pharma S.A Laboratories, Basel, Switzerland. 
# Prograf, Fujisawa Laboratories, Osaka, Japan. 
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maximal score of 5 and 10 gingival units (5 labial, 5 
lingual) were examined, a maximal score of 5 could 
be obtained after the sum of the values of the 10 
papillae examined were divided by 10. The meas- 
urements were made on the patient. In order to obtain 
an objective opinion on the clinical results and to 
assess the clinical significance of the variations of 
gingival overgrowth and the degree of satisfaction 
achieved by the non-dentist colleagues and the 
patients, the index developed by Harris and Ewart 
( H E I ) ~ ~  was scored by two non-dentist physicians 
(CJ, AA), three dentists (LA, MCF, JCV), and each 
of the patients. The gingival appearance was recorded 
as follows: 0, normal clinical appearance; 1, slight 
variation in the size of the gingiva; 2, moderate alter- 
, ation in the size of the gingiva; 3, severe alteration 
in the size of the gingiva. A mean score of the six 
measurements was obtained for each patient at the 
different time intervals. Clinical color photographs 
were recorded at baseline and 54 weeks using slide 
film.** 
After the gingival parameters were recorded, patients 
were instructed in oral hygiene techniques, and scaling 
and root planing (SRP) were performed by quadrants 
under local anesthesia with lidocaine 0.1 % epinephrine 
on 4 consecutive days, except patient 4 who was treated 
in 1 day. No antibiotic therapy was administered before 
or after these procedures were performed, but clorhex- 
idine (CHX) 0.12% mouthrinses were prescribed during 
the procedure and maintained for 1 week thereafter. 
At baseline, conversion of CsA to tacrolimus was 
carried out according to the protocol used by the 
transplant team (Table 1). SRP was performed in one 
session each month after baseline during the first 
6 months, and careful polishing of the teeth once 
every 2 weeks until month 6 and monthly until month 
12. Clinical data were recorded at baseline, at weeks 
2, 4, 8, 12, and 16, and 1 year (54 weeks) following 
conversion to tacrolimus. During each appointment, 
C 
al1 patients received instructions and reinforcement 
to optimize oral hygiene. 
To analyze whether there were statistically significant 
differences among means of SI between al1 periods, a 
repeated measures analysis of variance (ANOVA) test 
was applied.tt To test differences among the GE evo- 
lution levels measured with the SI, contrasts comparing 
the means of each time period to the subsequent time 
period were applied. 
RESULTS 
Except for one of the patients (patient 3), who pre- 
sented signs of liver rejection 8 months after the begin- 
ning of the study (treated with a short burst of steroids 
[ l  g of methylprednisolone daily for 3 consecutive 
days] and by increasing the dose of tacrolimus up to 
10 mg/d, with satisfactory results), no signs of liver or 
renal failure were observed after conversion to 
tacrolimus, and the clinical and laboratory parame- 
ters managed by the transplant team were within nor- 
mal limits during the study. Adverse effects from 
tacrolimus were reported by one patient (patient 1 ) 
who reported headaches. 
GE scores at conversion and at 2 , 4 ,  8, 12, 16, and 
54 weeks are shown in Table 2. lnitial GE scores 
showed high values when measured either by the SI 
(mean 4.9) or the HE1 (mean 3). Gingival overgrowth 
was reduced progressively during the study (Fig. l ) ,  
although the reduction was more evident after the 
second month. lnitial reduction after 2 weeks was 0% 
in three patients and 4% in patient 3, but at that time, 
the four patients reported an improvement of their 
symptoms in terms of a decrease in gingival pain 
and more comfort during oral hygiene procedures. 
One month after CsA withdrawal, GE decreased a 
mean of 3.5%, but the four patients felt a clear 
absence of gingival pain and a marked reduction in 
spontaneous gingival bleeding. Differences between 
means of SI values between baseline and 2- and 4- 
week recalls were not statistically significant. A large 
reduction of GE was observed at the 8-week recall, 
with a mean 22.5% decrease in GE (P<0.05). Subse- 
quently, statistically significant ( P  <0.05) dramatic 
changes were observed in al1 periods (Table 2) ,  
and gingival anatomy was considered clinically and 
esthetically normal by the non-dentist coworkers 
and by the patients at week 16. One year after CsA 
was withdrawn, the gingival size was considered clin- 
ically normal according to the HEI, except by one of 
the examiners who considered that one patient 
(patient 3) maintained a slight variation in the size 
of the gingiva (mean HEI: 0.16) (Fig. 2). In this 
patient and in patient 2, the gingiva did not achieve 
a satisfactory morphology according to two of the 
examiners. 
The repeated measures ANOVA results showed that 
there was a highly statistically significant ( P  <0.0005) 
difference between GE means at different time peri- 
ods. A contrast test identified six homogeneous groups 
showing progressively decreasing means. There were 
statistically significant differences between means of 
al1 periods with respect to subsequent periods, except 
** Ektachrorne 100 Plus Professional, Kodak Ltd., Heme1 Hempstead, 
U.K. 
t t  SPSS 10.0, SPSS Inc., Chicago, IL. 
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Table 2. 
Evolution of Gingival Enlargement Measured by SI and Harris-Ewart lndex (HEI) 
in the Four Patients 
Period (Weeks) 
Baseline 2 4 8 12 16 54 
lndex lndex lndex lndex lndex lndex lndex 
Patient lndex Value Value %* Value %* Value %* Value %* Value %* Value %* 
I SI 5.0 5.0 O 4.8 4 4.5 10 1.6 68 1 .O 80 0.2 96 
HE1 3.0 3.0 2.7 1.8 I .O 0.2 0.0 
Mean (SI only) 4.90 4.85 1 4.73 3.5 3.80 22.5 1.38 71.25 0.83 83 0.20 95.5 
* Percentage decrease with respect to baseline SI. 
Period (weeks) 
Figure l .  
Box plot ofmeasurements of gingivai overgrowth evolution 
throughout the study 
between baseline and week 2 means and between 
week 2 and 4 means. 
Length of time on CsA seemed to have no relation- 
ship to the completeness of resolution of gingival 
enlargement. Al1 four patients showed a similar pat- 
tern in the progression of the reduction of gingival 
enlargement. 
DlSCUSSlON 
Although the sample size of this preliminary study 
was small, the results may suggest that withdrawal 
of CsA and conversion to tacrolimus, together with 
an extensive plaque control program, may be an  
effective and safe alternative to reduce gingival 
enlargement severity in a short period of time. 
Mean initial (baseline) gingival overgrowth in this 
group of patients a s  measured by the SI was 4.9 and 
this may be considered as clinically severe, according 
to other similar studies, where scores of 2 to 3 or 
more were considered clinically ~ i ~ n i f i c a n t , ~ ~ ~ ~ ~ ~ ~ ~  
and represents overgrowth that warrants surgical exci- 
~ i o n . ~ ~  Regression of GE to a normal leve1 in the four 
cases reported in this study has not always been 
described previously in other similar studies. One 
possible explanation is that the patients we studied 
were not taking any other medication with proven 
effects on the gingiva except CsA, and although the 
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Case Series 
m 
Figure 2. 
A) lnitial gingival enlargernent in patient 3.6) Clinical picture of the 
gingiva upon cornpletion of treatment Note that in sorne interdental 
spaces, severa1 irregularities of the papillae persist 
initial GE was much more severe than in other simi- 
lar s t ~ d i e s , ' ~ ~ ~ ~  the GE was related exclusively to 
the administration of this drug. Other studies have 
demonstrated that conversion from CsA to tacrolimus 
produced a significant clinical reduction of GE even 
in cases where other drugs such as nifedipineI7 and 
phenytoin16 were administered together. In these 
cases, the reduction of GE was not so dramatic as in 
the cases reported in this article, which might be due 
to the fact that those drugs were not withdrawn. In the 
cases described by James et al.," three out of four 
patients did not show complete regression after 
9 months, but those patients were receiving CsA and 
calcium channel blocking agents to control their 
hypertension, and this association may have a syn- 
ergistic effect on the gingiva.'0729 Recently, we have 
reported a case of very severe GE in a patient taking 
CsA and phenytoin;16 although a significant im- 
provement was observed after 6 months of CsA with- 
drawal, total reduction was not achieved due to con- 
tinued administration of phenytoin, which could not 
be withdrawn. 
The presence of gingival inflammation could be 
another factor that might be responsible for the incom- 
plete reduction of GE once CsA has been withdrawn.13 
ln our study, an intensive oral health program accom- 
panied the withdrawal of CsA. The role of gingival 
inflammation in the GE regression rate seems to be 
important. In the cases reported by Thorp et a1.,18 
from six patients exhibiting GE, two patients reverted 
to a normal gingival status in 4 months, one in 8 mon- 
ths, one in 12 months (complete resolution: 67%), and 
two patients did not achieve complete regression after 
1 year, although the improvement was significant. 
These two patients displayed a more severe GE, and 
neither was taking any other medication with known 
effects on the gingiva. However, initial scores of the 
gingival hyperplasia index were much lower than in 
our patients. No data regarding the hygiene meas- 
ures carried out during their study, if any, were 
described. This may mean that the presence of plaque 
and inflammation might delay the regression of GE 
in these patients once CsA is switched to tacrolimus. 
In our cases, professional hygienic procedures were 
extensively carried out. Although during the first 
weeks after CsA withdrawal the patients could not 
effectively remove the plaque due to the severity of 
GE, professional measures such as scaling and root 
planing and polishing were performed thoroughly dur- 
ing the study, so the patients showed minimal gingi- 
val inflammation. 
The exact role played by plaque control and with- 
drawal of CsA on the improvement of GE remains 
unclear. It has been shown in cases of GE that patients 
undergoing professional cleaning experienced a sta- 
tistically significant decrease of 12.1 % in the gingival 
overgrowth, and those who also underwent scaling and 
curettage had a decrease of 18.2% between months 6 
and 12 after t ran~~lanta t ion .~~ Kantarci et al.31 reported 
that after oral hygiene instructions, supra- and sub- 
gingival scaling, polishing, and gingival curettage, the 
initial gingival overgrowth scores were reduced from 
53.40% to 32.13% after 8 weeks, a reduction of 2 1.27%. 
Although we did not perform closed curettage in our 
patients, which offers no benefit when combined with 
scaling and root planing, the initial effect of scaling 
and root planing on GE reduction seems to be import- 
ant, at least in terms of reduction of the inflammation. 
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The patients initially observed a more comfortable 
gingival sensation and disappearance of the pain in 
10 days. Moreover, after 8 weeks, the reduction of GE 
in our patients was lo%, 21%, 39%, and 20%, respec- 
tively. This represented greater improvement than 
that achieved when tooth c ~ e a n i n ~ , ~ ~  scaling and root 
planing,30 closed ~ u r e t t a ~ e , ~ ~  or even gingivectomy32 
are used, and these findings may suggest that the 
differences are due to the cessation of the effect of 
CsA. However, there are contradictory results in this 
respect and, paradoxically, other studies have shown 
that patients receiving hygienic procedures present 
fewer benefits in their GE once CsA is withdrawn.17 
This is an interesting and curious observation, and in 
light of our experience, we cannot offer a satisfactory 
explanation. One possible cause is that those GE that 
are more fibrous respond less favorably to hygiene 
measures than those that display a more severe 
inflammatory/edematous component. Patient 3 in our 
study initially displayed a very inflammatory/ede- 
matous gingival appearance and was the patient who 
responded more quickly to the change of medica- 
tion. In this regard, it would be very interesting to 
know how much influence the presence of plaque 
and gingival inflammation has in the regression of 
GE, in terms of quantity and length, and the exact role 
that the withdrawal of the drug plays. The small num- 
ber of cases in this report does not permit assessment 
of these factors and should be analyzed in a separate 
study designed to answer these questions. 
Length of time in which GE reduction is achieved 
showed some variation, but it seems that 4 months 
are necessary to achieve satisfactory results, at least 
in terms of esthetics. In our study, the four patients 
showed satisfaction with the appearance of their gin- 
giva after 4 months. Patients reported by James 
et al.17 were satisfied with the esthetic appearance of 
their gingiva after 6 months, although the final GE 
scores were higher than in our study and the per- 
centage of reduction was lower, except for patient 3 
in the James et al. study who showed an 82.3% 
improvement. Regression of gingival hyperplasia was 
also rapid in the cases described by Thorp et a1.,18 
and severa1 patients displayed complete regression by 
4 months, although in others, the reduction contin- 
ued up to 1 year and was not complete. It has been 
stated that the lack of complete response after 6 to 
9 months may be due to physiological inability for tis- 
sue remodeling, since breakdown of large numbers 
of extracellular matrix macrornolecules is necessary 
in these cases.17 The results of our preliminary study 
do not support that observation, and 4 months seem 
adequate to achieve the disappearance of the hyper- 
trophic tissue. It may be that differences in the 
amount of the inflammatory component might help 
to explain these discrepancies. Although our patients 
showed a more severe GE than in other similar stud- 
ies, perhaps the inflammatory component was also 
higher, and this was responsible for the reduction of 
GE. This is achieved sooner in edematous responses 
than in cases of a more fibrotic nature. These two 
gingival patterns, either fibrotic, with a firm fibrous 
nodular aspect, or edematous, accompanied by pink 
coloration, erythema, swollen aspect, gingival mobil- 
ity on probing, and spontaneous bleeding, have been 
previously reported.lg In addition, an important con- 
sideration regarding the different healing responses 
might be ethnic differences in the populations that 
are being studied. 
Other questions that require additional study include 
the role of come variables which may influence the 
amount and progression of the GE reduction, once CsA 
is changed to tacrolimus, for example, the preexisting 
leve1 of GE and the length of time of GE. Considering 
the small number of cases in our study, we cannot 
respond to the first question, since al1 of the patients 
initially showed the same degree of GE and the 
regression of GE showed a uniform pattern. With 
respect to the role of the duration of GE, we could 
not state this variable exactly; however, the reduction 
was achieved in the same way in al1 four patients, 
although the time the patients had been taking CsA 
was different. 
One of the initial obstacles faced in this study was 
finding enough patients who met the study criteria. 
Transplantation teams are seldom predisposed to 
change the immunosuppressive regimen unless some 
systemic side effects due to CsA appear. Despite some 
studies in which withdrawal of CsA has been carried out 
due only to the presence of G E , ' ~ , ' ~ ~ * ~  it is difficult to 
get a change in the immunosuppressant if GE appears 
as the only complication. Tacrolimus is a xenobiotic 
immunosuppressant isolated from microbial broths 
(Streptomyces t s~bakens i s )~~  that acts through the inhi- 
bition of interleukin (1L)-2 and other growth-promoting 
cytokine dependent T-cell activation.14 Different stud- 
ies conducted in the United States and Europe have 
demonstrated that tacrolimus shows similar patient and 
graft survival in both liver and kidney transplantation 
as CsA, and that there is a consistent statistically sig- 
nificant advantage for tacrolimus with respect to acute 
rejection rate.34 Since tacrolimus has been demon- 
strated to be a safe and secure alternative to CsA, its 
use has become widespread in solid organ transplan- 
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tation in cases  of primary immunosuppression,34~35 
and conversion therapy to tacrolimus successfully pro- 
vides an  alternate treatment a s  rescue therapy in cases 
of r e j e ~ t i o n . ~ ~  
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